Archive | Publications

Melanoma Journal Articles for October 2018

Cancer Epidemiology, Biomarkers and Prevention Reviews An Epidemiological Review of Diet and Cutaneous Malignant Melanoma Keming Yang, Teresa T. Fung and Hongmei Nan DOI: 10.1158/1055-9965.EPI-18-0243 Published October 2018 BMJ Cancer genetics Short report Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations Hildur Helgadottir, Paola Ghiorzo, Remco van Doorn, Susana […]

Read the full story

Posted in Scientific Publications

European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma

Source: Hospital Healthcare Europe, October 2018 The European Commission (EC) had approved the use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to treat adults with advanced BRAF-mutant melanoma. The EC’s decision is based on results from the Phase 3 COLUMBUS trial, which demonstrated 14.9 months median progression-free survival and 33.6 months median overall survival with the combination […]

Read the full story

Posted in Melanoma News, Regulatory, Publications

Melanoma Journal Articles for September 2018

Experimental Cell Research Melanoma-released exosomes directly activate the mitochondrial apoptotic pathway of CD4+ T cells through their microRNA cargo JiZhoua1YiYanga1WenWenWangaYuanZhangbZhengRongChencChuangLiHaocJinPingZhanga https://doi.org/10.1016/j.yexcr.2018.08.030 Available online 25 August 2018 Dove Press E2F3 promotes cancer growth and is overexpressed through copy number variation in human melanoma Authors Feng Z, Peng C, Li D, Zhang D, Li X, Cui F, Chen Y, He […]

Read the full story

Posted in Scientific Publications

NICE turns down Opdivo for adjuvant melanoma therapy

England’s cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor

Read the full story

Posted in Melanoma News, Regulatory